SCHEMBL24733403

SCHEMBL24733403

COc1ccc(OC)c(CCNCc2cc(Cl)cc(Cl)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.60
HTR2C P28335 3/20 0.60
ADRA1A P35348 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47
ALKBH5 Q6P6C2 1/20 0.46
BCHE P06276 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30277338 0.92 HTR2A (0.55) HTR2AHTR2CADRA1ATAAR1MEN1
SCHEMBL24733587 0.92 HTR2A (0.55) HTR2AHTR2CADRA1ATAAR1MEN1
SCHEMBL31218198 0.88 HTR2A (0.54) HTR2AHTR2CBCHE
SCHEMBL24734851 0.88 HTR2A (0.54) HTR2AHTR2CBCHE
SCHEMBL31188804 0.87 HTR2A (0.50) HTR2AHTR2CKMT2AALDH1A1MTNR1A
SCHEMBL31218130 0.87 HTR2A (0.50) HTR2AHTR2CMEN1MAPTKMT2A
SCHEMBL24734849 0.87 HTR2A (0.50) HTR2AHTR2CMEN1MAPTKMT2A
SCHEMBL24734850 0.87 HTR2A (0.50) HTR2AHTR2CKMT2AALDH1A1MTNR1A
Hydrochloric Acid SCHEMBL30861232 0.87 HTR2A (0.53) HTR2AHTR2CBCHE
Hydrochloric Acid SCHEMBL29171810 0.87 HTR2A (0.53) HTR2AHTR2CBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282712-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS ATAI THERAPEUTICS INC (US) 2025-09-11 US disclosed
US-20250268846-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS ATAI THERAPEUTICS INC (US) 2025-08-28 US disclosed
US-12351537-B2 Dimethoxyphenylalkylamine activators of serotonin receptors ATAI THERAPEUTICS, INC. (US) 2025-07-08 US disclosed
US-12343319-B2 Compositions and methods for treatment of diseases and disorders ATAI THERAPEUTICS, INC. (US) 2025-07-01 US disclosed
US-20240366531-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS Atai Therapeutics Inc. 2024-11-07 US disclosed
US-20240294461-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS Atai Therapeutics Inc. 2024-09-05 US disclosed
US-11926574-B2 Dimethoxyphenylalkylamine activators of serotonin receptors Atai Therapeutics Inc. (US) 2024-03-12 US disclosed
CN-117500487-A Dimethoxy phenyl alkylamine activators of serotonin receptors 恩泰奥吉尼克斯生物科学公司 2024-02-02 CN disclosed
US-20230138118-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS Atai Therapeutics Inc. 2023-05-04 US disclosed
US-20230138118-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS Atai Therapeutics Inc. 2023-05-04 US disclosed
US-20230138118-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS Atai Therapeutics Inc. 2023-05-04 US disclosed
WO-2022261240-A2 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS ATAI Life Sciences AG (DE) 2022-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12343319-B2 Compositions and methods for treatment of diseases and disorders HCRTR1, H1-10, RAB10 HTR2A 480/4885HTR2C 442/4885ADRA1A 543/4885
US-11926574-B2 Dimethoxyphenylalkylamine activators of serotonin receptors HTR1A, HTR7, HTR4 HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885
US-20230138118-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS HTR1A, HTR7, HTR4 HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885
US-12351537-B2 Dimethoxyphenylalkylamine activators of serotonin receptors HTR1A, HTR7, HTR4 HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885
US-20250268846-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS HCRTR1, RAB10, H1-10 HTR2A 480/4885HTR2C 465/4885ADRA1A 513/4885
US-20250282712-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS HTR1A, HTR7, HTR4 HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885
US-20240294461-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS HTR1A, HTR7, HTR4 HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885
US-20240366531-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS HCRTR1, H1-10, RAB10 HTR2A 480/4885HTR2C 442/4885ADRA1A 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.